Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 9/20 | 0.72 |
| ▸ | ICMT | O60725 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942305 | 0.92 | SERPINE1 (0.81) | SERPINE1ICMTLMNAADORA1 | |
| SCHEMBL4937574 | 0.88 | SERPINE1 (0.83) | SERPINE1ICMTALDH1A1TP53MAPT | |
| SCHEMBL4750090 | 0.85 | SERPINE1 (0.83) | SERPINE1ICMTALDH1A1LMNA | |
| SCHEMBL3861263 | 0.85 | SERPINE1 (0.67) | SERPINE1ICMTALDH1A1LMNATP53 | |
| SCHEMBL3948740 | 0.84 | SERPINE1 (0.82) | SERPINE1ICMTADORA1 | |
| Aleplasinin SCHEMBL3861891 | 0.84 | SERPINE1 (1.00) | SERPINE1ICMT | |
| Aleplasinin SCHEMBL29377702 | 0.84 | SERPINE1 (1.00) | SERPINE1ICMT | |
| SCHEMBL3858380 | 0.84 | SERPINE1 (0.86) | SERPINE1ICMTADORA1 | |
| SCHEMBL4939557 | 0.82 | SERPINE1 (0.60) | SERPINE1ICMTADORA1 | |
| SCHEMBL3856116 | 0.82 | SERPINE1 (0.76) | SERPINE1ICMTADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-09-04 | — | — | US | disclosed |
| US-7368471-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1844771-A2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | Wyeth (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1397130-B1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-27 | — | — | US | disclosed |
| US-7074817-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1397130-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | disclosed |
| WO-2003000253-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885ICMT 4550/4885ALDH1A1 2351/4885 |
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, TFPI, F12 | SERPINE1 1/4885ICMT 2384/4885ALDH1A1 1252/4885 |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F12 | SERPINE1 1/4885ICMT 2376/4885ALDH1A1 1250/4885 |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | TFPI, SERPINE1, PLAT | SERPINE1 2/4885ICMT 2468/4885ALDH1A1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.